IP Library Granted Patent US 8,883,448
Granted Patent B2
US 8,883,448 · App. 12/623,062 · Granted Nov 11, 2014

Mutated

Inventors: Jeffrey Schlom (Potomac, MD); Scott Abrams (Amherst, NY)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
C07K14/82A61K39/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,448
App. No.
12/623,062
Granted
Nov 11, 2014
Kind
B2
Abstract

Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8 + CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in vivo-primed CD8 + CTL precursors.

Claims (2)

1. An isolated DNA sequence encoding a mutant ras peptide consisting of SEQ ID NO: 11.

2. A plasmid or virus vector comprising the DNA sequence of claim 1 .

Continuity (3)
Continuation 09155590
Continuation In Part 08635344 · Apr 19, 1996
Related Publication 20100074945A1 · Mar 25, 2010